Skip to content

Study · Not a test of the peptide alone · 2003

1 result

[Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome].

Gao ZC, Zhu JH, Sun Y, Ding XL, Ma JS, Cui YX, Du XK, Gao T, He QY

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue1 Jun 2003Cited by 19 (Europe PMC)

PMID12837162 (opens in a new tab)PepBankPUB-12837162
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneCase report or seriesEfficacy outcome

    In patients with SARS, timely treatment with ribavirin, methylprednisolone and immunoenhancers (interferon alpha-2b, thymosin-alpha1) was reported as efficacious to a certain extent in controlling disease progression.

    In plain wordsIn people with SARS, early treatment with several drugs, including thymosin alpha‑1, helped control the disease to some extent.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedControl of SARS disease progression
    Study

    n: not reported in source

    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    (3) Timely administration of Ribavirin, Methylprednisolone, immunoenhancer (such as interferon alpha-2b, thymosin-alpha1) to SARS patients was efficacious to certain extent in controlling the development of the disease.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.